SWM
GTBP icon

SeaCrest Wealth Management’s GT Biopharma GTBP Stock Holding History

SeaCrest Wealth Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5K Buy
50,100
+100
+0.2% +$41 ﹤0.01% 550
2026
Q1 		$20.4K Hold
50,000
– – ﹤0.01% 632
2025
Q4 		$36.6K Buy
+50,000
New +$35.5K ﹤0.01% 629

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

SeaCrest Wealth Management's GTBP Position: Q2 2026 in Review

SeaCrest Wealth Management increased its GT Biopharma (GTBP) stake by 0.2% in Q2 2026, buying an estimated $41 and bringing the position to 50,100 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #550.

SeaCrest Wealth Management first reported a position in GTBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $36.6K in Q4 2025. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • SeaCrest Wealth Management held 50,100 shares of GT Biopharma worth $24.5K as of Q2 2026.
  • SeaCrest Wealth Management bought 100 GT Biopharma shares in Q2 2026, an estimated $41.
  • GT Biopharma made up ﹤0.01% of SeaCrest Wealth Management's portfolio in Q2 2026, its #550 holding.
  • SeaCrest Wealth Management first reported a position in GT Biopharma in Q4 2025 and has held it in 3 quarters since.
  • SeaCrest Wealth Management's GT Biopharma position peaked at $36.6K in Q4 2025.
  • 59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on SeaCrest Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.